MedTrace Logo

Observational Program Neo-Penotran® Forte

NCT01335373 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 13024

Last updated 2016-07-25

No results posted yet for this study

Summary

Vaginitis is the most common gynecologic diagnosis in the primary care setting. In approximately 90 percent of affected women, this condition occurs secondary to bacterial vaginosis, vulvovaginal candidiasis, trichomoniasis or mixed infection.

Neo-Penotran Forte is registered for treatment of these most common vaginal infections. Efficacy and safety of this product is already established, and this observational study was designed to learn more about practical use of Neo-Penotran® Forte in real life setting.

Conditions

  • Vaginal Candidiasis
  • Bacterial Vaginosis
  • Trichomonal Vaginitis

Interventions

DRUG

Metronidazole/Miconazole (Neo-Penotran Forte, BAY86-5276)

Patients older than 18 years with previously taken decision of their gynecologist to prescribe Neo-Penotran Forte according to registered indications, and microbiological tests were performed.

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2011-12-31
Completion
2015-04-30

Countries

  • Kazakhstan

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01335373 on ClinicalTrials.gov